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Abstract 
Neuroblastoma is a childhood cancer that originates from precursor cell of 
sympathetic nervous system, occurring primarily in children under the age of 5 
years. The disease is highly heterogeneous, ranging from spontaneous 
regression to rapid progression with high death rate in pediatric oncology. 
Expression profiling studies of Neuroblastoma primary tumors have identified 
many miRNAs whose expression levels have been significantly associated with 
poor patient survival. MiR-34a is a member of an evolutionarily conserved 
miRNA family, miR-34s. Mir34a functions as tumor suppressor in 
Neuroblastoma and the inactivation and absence of miR-34a has been shown 
related to the pathogenesis of a variety of tumors. Several genes have been 
shown to be direct miR-34a targets, encoding for proteins involved in 
proliferation, invasion and apoptosis. However, it is likely that miR-34a 
regulates many additional, as yet unconfirmed targets, since bioinformatic 
predictions suggest that several hundred of mRNAs contain matches to the 
miR-34a seed sequence. To address this question, here, we describe a global 
analysis of the effect of miR-34a expression at early time points (6 and 12 hrs) 
on proteome using a shotgun analysis with post-metabolic differential labeling 
in two different aggressive Neuroblastoma cell lines. This technology allow us 
to identify 2082 proteins, of which 172 were found differentially regulated, 
with 113 proteins being down- and 68 up-regulated. Computational analyses 
were employed to assign to each identified peptide its protein name and its 
specific level of regulation. When considering protein with a predicted seed-
matching site among the protein identified, we found that only 33 proteins 
retain seed sequence in the 3’ UTR of the corresponding mRNA, as predicted 
by PITA tool. By combining the results generated by shotgun and Kaplan 
Meier for overall survival analyses, we found seven proteins/genes correlated 
to worse clinical outcome when overexpressed  in NBL. These genes are 
involved in the differentiation (LYAR, CTCF), apoptosis and proliferation 
(TGM2, Ki67), molecular transport (TIMM13 and ABCF2) and several 
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metabolic pathway (ALG13). Furthermore, these proteins are strongly linked 
each other and their impairment affects several pathways, including those 
signaling pathways such as TGF-β, Wnt and Src. Here, we comprehensively 
demonstrate the capabilities of miR-34a to target simultaneously components 
of several cancer signaling cascade, involved in Neuroblastoma progression. 
The level of this analysis was able to deeply understand which other protein are  
targeted and at what specific time of action are then down-regulated by 
miR34a, given a second level of target identification and showing the 
importance of this action in Neuroblastoma as one of the prominent 
phenomena occur to counteract the progression of tumorigenesis. 
Moreover, we demonstrated that the magnitude of miR-34a effect on protein 
expression changes occurs at early time when compared to the later proteome 
output. Finally, to assess trend analysis, of the proteins differentially expressed 
at different time points (6h, 12h and 24h), Lorenz curve and Gini coefficient 
were evaluated for each protein, observing that several proteins were 
dinamically regulated and highlighting that machinery involving protein 
downregulation, by miRNA, are not linear. Our data along with previous 
studies strongly suggest the potential therapeutic usefulness of miR-34a that 
could offer better chance of therapeutic success.  
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1. Introduction 
1.1 Neuroblastoma 
Neuroblastoma (NB) is the most common extra-cranial solid tumor of 
childhood. It has an incidence of 1 to 5 per million children per year and it is 
responsible for approximately 15% of all childhood cancer mortality. NBs 
originate from immature sympathetic nervous system cells, the so-called 
neuroblasts. Most NBs (90%) are diagnosed before the age of 5 years, and the 
median age of occurrence is approximately 22 months [1]. The vast majority of  
tumors arise sporadically, although some familial cases are described. Most of 
the tumors are found in the abdomen (65%), often in the adrenal medulla, or 
elsewhere in the human body where sympathetic nervous system components 
are present [2]. NBs belong to the subgroup of small round blue cell tumors 
and can often pose a challenge to the pathologist because of their similarities 
with lymphomas, rhabdomyosarcomas, the Ewing family of tumors and 
desmoplastic round cell tumors. NB tumors are divided into different stages 
according to the localization and extension of the primary tumor and the 
absence or presence of distant metastases. The International Neuroblastoma 
Risk Grouping Staging System takes into account the extent of disease at 
diagnosis as well as risk factors and stages defined using imaging to classify 
NBs from patients from all over the world in a uniform manner [3,4]. 
Metastatic tumors (stage M) have a dismal prognosis, whereas patients with 
locoregional tumors (L1 and L2) usually have an excellent outcome. Stage Ms 
tumors (where ‘s’ stands for special and metastatic disease is confined to skin, 
liver and/or bone marrow) are characterized by spontaneous regression or 
differentiation even without any form of therapy. Although localized disease 
can be treated by surgery alone, the standard therapy for patients with 
metastatic disease usually comprises intensive induction chemotherapy, local 
surgery and myeloablative chemotherapy followed by autologous stem cell 
transplant, external radiotherapy and retinoic acid treatment. The overall 
survival rate for children with metastatic NB is approximately 40%, despite 
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this intensive multimodal therapy. The survival of children with NB also 
correlates strongly with age at diagnosis. Children under 1 year at diagnosis 
usually have a favorable prognosis, whereas prognosis of older children 
presenting with NB is poor. 
Currently, there are worldwide efforts to construct a robust risk stratification 
system. Before any treatment, patients will be put into a risk category, 
according to a combination of parameters such as age (younger or older than 
18 months), stage, pathology,  MYCN status, other genetic aberrations such as 
11q loss and ploidy [3,4]. The use of the International Neuroblastoma Risk 
Groups will allow international comparisons of different risk-based therapeutic 
approaches in the same patient population and greatly facilitate joint 
international collaborative studies in NB. Elucidation of the molecular 
pathways involved will enable researchers to stratify the disease and to adapt 
therapy. 
 
1.2 Genomic analysis of Neuroblastoma 
The clinically heterogeneous nature of NB depends, in part, by its biological 
and genetic heterogeneity. During the past decade, several genetic aberrations 
have been discovered in NB primary tumors and cell lines that have been 
shown to correlate with the various clinical features. Moreover, genetic and 
molecular findings are now routinely incorporated into therapeutic decision 
making [5]. The most important genetic defects that have been detected in NB 
are briefly discussed below. 
Ploidy According to their DNA index, NBs can be divided into a group with a 
near-diploid nuclear DNA content (about 45% of NBs) and those with a near-
triploid DNA content (about 55%). DNA index is a prognostic marker for 
patients younger than 2 years with disseminated disease [6-8]. It was suggested 
that a near-triploid DNA content, which is found more often in localized or Ms 
NB, was due to the fact that these tumors have a fundamental defect in mitosis 
leading to gains and losses of whole chromosomes, whereas locoregional or 
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metastatic tumors with a near diploid DNA content have a fundamental defect 
in genome stability leading to chromosomal rearrangements such as 
unbalanced translocations. 
MYCN amplification  The MYCN oncogene was found to be amplified in 20 
to 25% of NBs, and is usually present in the form of double-minutes 
(chromosome fragments) or homogeneously staining regions. Evidence for a 
direct involvement in the development of NB was obtained through the 
construction of a mouse NB model in which a human MYCN cDNA was 
placed under the control of a tyrosine hydroxylase promoter, leading to 
development of NB [9]. Amplification of the MYCN gene is most  often found 
in high-stage tumors and is a marker for poor outcome [10,11]. 
Although MYCN regulates a large number of downstream genes, only a 
handful of key targets have yet been identified. Interestingly, high MYCN 
target gene expression is not restricted to MYCN-amplified NBs but is also 
apparent in high-stage MYCN non-amplified tumors, indicating that common 
pathways are altered in high-stage tumors [12]. 
Chromosome 3p loss  Chromosome 3p loss is often found in association with 
11q loss and typically occurs in tumors without MYCN amplification or 1p 
deletion [13-16]. Furthermore, tumors with 3p loss are a hallmark of NB 
patients with older age at diagnosis, suggesting that 3p loss is a late event in 
NB oncogenesis. At present, three common regions of deletions on the short 
arm of chromosome 3 can be delineated [17]. Two of these SRDs were found 
to coincide with SRDs defined in more common cancers, such as breast and 
lung cancer [17]. These regions contain several candidate tumor suppressor 
genes, including the RASSF1A gene.  
Chromosome 11q loss  Deletions of the long arm of chromosome 11 have been 
identified in 15 to 22% of primary NBs. Chromosome 11q deletions are often 
found in high-stage tumors without MYCN amplification and with intact 
chromosome 1p. Chromosome 11q loss was shown to be associated with 
reduced time of progression-free survival [18,19]. Recently, two common 
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regions of deletion on the long arm of chromosome 11 were delineated and 
CADM1 was identified as a candidate chromosome 11q tumor suppressor gene 
[20-22]. 
Chromosome 1p loss  Deletion of chromosome 1p sequences is more common 
in high-stage tumors and is usually associated with MYCN amplification. The 
prognostic significance of 1p loss has long been controversial but current 
evidence suggests that allelic loss of 1p36 sequences predicts an increased risk 
of relapse in patients with localized tumors [18]. 
Chromosome 17q gain  Gain of chromosome 17q  is the most common genetic 
aberration, occurring in approximately 80% of NBs [23]. It often results from 
unbalanced translocations with chromosome 1p or chromosome 11q [23,24], 
although other partner chromosomes can be involved. The involvement of 
chromosome 1 and chromosome 17 in the etiology of NB was further 
reinforced by the identification of a constitutional balanced t(1;17) 
translocation in a patient with NB [25]. 
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1.3 MiRNA and their role in tumorigenesis  
MiRNAs are non-coding, single-stranded RNAs of ~22 nucleotides and 
constitute a novel class of gene regulators that are found in both plants and 
animals. They negatively regulate their targets in one of two ways depending 
on the degree of complementarity between the miRNA and the target. First, 
miRNAs that bind with perfect or nearly perfect complementarity to protein 
coding mRNA sequences induce the RNA-mediated interference (RNAi) 
pathway. Briefly, mRNA transcripts are cleaved by ribonucleases in the 
miRNA-associated, multiprotein RNAinduced-silencing complex (miRISC), 
which results in the degradation of target mRNAs. This mechanism of miRNA-
mediated gene silencing is commonly found in plants, but has also been shown 
to occur in mammals. However, most animal miRNAs are thought to use a 
second mechanism of gene regulation that does not involve the cleavage of 
their mRNA targets. These miRNAs exert their regulatory effects by binding to 
imperfect complementary sites within the 3′ untranslated regions (UTRs) of 
their mRNA targets, and they repress target-gene expression post-
transcriptionally, apparently at the level of translation, through a RISC 
complex that is similar to, or possibly identical with, the one that is used for the 
RNAi pathway (Figure 1).  
Together with translational control, miRNAs use this mechanism in order to 
reduce the protein levels of their target genes, but the mRNA levels of these 
genes are barely affected. The biogenesis of miRNAs has only recently been 
elucidated. MiRNAs, which generally seem to be transcribed by RNA 
polymerase II, are initially made as large RNA precursors that are called pri-
miRNAs. The pri-miRNAs are processed in the nucleus by the RNase III 
enzyme, Drosha, and the double-stranded- RNA-binding protein, Pasha (also 
known as DGCR8), into ~70-nucleotide pre-miRNAs, which fold into 
imperfect stem-loop structures. 
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The pre-miRNAs are then exported into the cytoplasm by the RAN GTP-
dependent transporter exportin 5 and undergo an additional processing step in 
which a double- stranded RNA of ~22 nucleotides in length, referred to as the 
miRNA:miRNA* duplex, is excised from the pre-miRNA hairpin by another 
RNAse III enzyme, Dicer. Subsequently, the miRNA:miRNA* duplex is 
incorporated into the RISC complex. The mature miRNA strand is 
Figure 1: The biogenesis of microRNAs. MicroRNA (miRNA) genes are generally transcribed by 
RNA Polymerase II (Pol II) in the nucleus to form large pri-miRNA transcripts, which are capped 
(7MGpppG) and polyadenylated (AAAAA). These pri-miRNA transcripts are processed by the RNase 
III enzyme Drosha and its co-factor, Pasha, to release the ~70-nucleotide pre-miRNA precursor product. 
(Note that the human let-7a-1 miRNA is shown here as an example of a pre-miRNA hairpin sequence. 
The mature miRNA sequence is shown in red.) RAN–GTP and exportin 5 transport the pre-miRNA into 
the cytoplasm. Subsequently, another RNase III enzyme, Dicer, processes the pre-miRNA to generate a 
transient ~22- nucleotide miRNA:miRNA* duplex. This duplex is then loaded into the miRNA-
associated multiprotein RNA-induced silencing complex (miRISC) (light blue), which includes the 
Argonaute proteins, and the mature single-stranded miRNA (red) is preferentially retained in this 
complex. The mature miRNA then binds to complementary sites in the mRNA target to negatively 
regulate gene expression in one of two ways that depend on the degree of complementarity between the 
miRNA and its target. miRNAs that bind to mRNA targets with imperfect complementarity block target 
gene expression at the level of protein translation (lower left). However, recent evidence indicates that 
miRNAs might also affect mRNA stability (not shown). Complementary sites for miRNAs using this 
mechanism are generally found in the 3′ untranslated regions (3’ UTRs) of the target mRNA genes. 
miRNAs that bind to their mRNA targets with perfect (or nearly perfect) complementarity induce target-
mRNA cleavage (lower right). miRNAs using this mechanism bind to miRNA complementary sites that 
are generally found in the coding sequence or open reading frame (ORF) of the mRNA target. 
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preferentially retained in the functional RISC complex and negatively regulates 
its target genes. Many researchers failed to appreciate the importance of 
miRNAs when they were initially described more than a decade ago. This is 
because the first miRNA gene that was identified, lin-4, was thought to be 
unique to the roundworm Caenorhabditis elegans and control the timing and 
progression of the nematode life cycle. However, the identification of hundreds 
of miRNAs within worm, fly and mammalian genomes by traditional cloning 
techniques and bioinformatics has captured the attention of scientists 
specializing in various different fields. Most human miRNAs are found within 
introns of either protein-coding or noncoding mRNA transcripts. The 
remaining miRNAs are either located far from other transcripts in the genome, 
within the exons of noncoding mRNA genes or within the 3′ UTRs of mRNA 
genes, or they are clustered with other miRNA genes, including a cluster on 
chromosome that is comprised of novel miRNAs. miRNAs can be grouped into 
families on the basis of sequence homology, which is found primarily at the 5′ 
end of the mature miRNAs, but whether members of the same miRNA family 
control similar biological events remains to be seen. Many miRNAs are 
evolutionarily conserved from worms to humans, which implies that these 
miRNAs direct essential processes both during development and in the adult 
body. Several studies have shown a strong correlation between abrogated 
expression of miRNAs and oncogenesis. Our study recently provided 
evidences that support this mechanism in the Medulloblastoma (MB) tumors. 
Indeed, we have recently shown that miR199b-5p, through direct targeting of 
Hes1 gene, key effector of the Notch pathway, exerts onco-suppressor 
functions in MB cells. We reported that over-expression of miR199b-5p 
impairs proliferation of different MB cells and affects survival of the MB stem-
cell subpopulation [26]. Another report demonstrated that miR-21 is 
upregulated in glioblastoma. This gene was found to be expressed at a 5–100-
fold higher rate in gliomas than in normal tissue. Antisense studies of miR-21 
in glioblastoma cell lines showed that this miRNA controls cell growth by 
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inhibiting apoptosis but does not affect cell proliferation, which implies an 
oncogenic role for this miRNA. Finally miR34a expression was reported 
significantly downregulated in several human cancers, and aberrant CpG 
methylation of its promoter was observed in prostate carcinomas and primary 
melanomas, as well as in several tumor cell lines, [27] and loss of miR-34 has 
been linked to chemoresistance of cancer. 
 
 
 
Figure 2: MicroRNAs can function as tumour suppressors and oncogenes. a |In normal tissues, 
proper microRNA (miRNA) transcription, processing and binding to complementary sequences on the 
target mRNA results in the repression of target-gene expression through a block in protein translation 
or altered mRNA stability (not shown). The overall result is normal rates of cellular growth,  
proliferation, differentiation and cell death. b The reduction or deletion of a miRNA that functions as a 
tumour   suppressor leads to tumour formation. A reduction in or elimination of mature miRNA levels 
can occur because of defects at any stage of  miRNA biogenesis (indicated by question marks) and 
ultimately leads to the inappropriate expression of the miRNA-target oncoprotein  (purple squares). 
The overall outcome might involve increased proliferation, invasiveness or angiogenesis, decreased 
levels of apoptosis, or undifferentiated or de-differentiated tissue, ultimately leading to tumour 
formation. c The amplification or overexpression of a miRNA that has an oncogenic role would also 
result in tumour formation. In this situation, increased amounts of a miRNA, which might be produced 
at inappropriate times or in the wrong tissues, would eliminate the expression of a miRNA-target 
tumour-suppressor gene (pink) and lead to cancer progression. Increased levels of mature miRNA 
might occur because of amplification of the miRNA gene, a constitutively active promoter, increased 
efficiency in miRNA processing or increased stability  of the miRNA (indicated by question marks). 
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1.4 miR-34a  
MiR-34 is an evolutionary conserved family of miRNAs consisting of three 
members in vertebrates (miR-34a, miR-34b and miR-34c), and one orthologue 
sequence in invertebrates species. 
In human, miR-34a precursor sequence maps on the short arm of chromosome 
1 in position p36.23; while, miR-34b and miR-34c on long arm of the 
chromosome 11 in position q23.1 (Figure 3). 
 
 
Several groups have recently reported that the three-miR34 family members 
are direct targets of p53 transcription factor [28]; in particular, miRNA 
expression profiles of five different studies reported miR-34a as the most 
significantly induced miRNA after activation of p53.  
p53 binding sites were identified 30Kb and 3kb upstream respectively of the 
miR-34a and cluster miR34b/c loci, and CHIP (chromatin 
immunoprecipitation) performed had confirmed the p53 binding. 
However ectopic expression of miR-34a recapitulated p53 mediated effects 
including cell cycle arrest and induction of apoptosis and senescence-like 
phenotype. On the other hand, inhibition of miR-34a functions via specific 
LNA (locked nucleotide analogs) impaired p53-induced apoptosis, upon DNA 
Figure 3: p53 Binding site within promoter region of miR34 Family. Schematic representation of p53 
binding sites identified upstream 30Kb and 3kb respectively of the miR34a and cluster miR34b/c loci. 
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damage induction [29]. Therefore, miR-34a can be, in some cases, not only 
sufficient but also required for mediation of tumor suppression by p53. 
Until now, several miR-34a targets have been experimentally validated, 
including CDK4/6, cyclin E2, cyclin D1, E2F5, MET, Bcl2, MYCN and 
SIRT1. The high similarity among the three processed miR34 family members 
suggested that they might have the same targets. However, miR-34a and the 
cluster miR34b/c have distinct tissue-specific expression patterns, with miR-
34a presents at highest levels in the mouse brain, and low or moderate levels in 
other tissues, whereas miR-34b and miR-34c most highly expressed in lung 
[30].  
Recently, Ji and colleagues had shown in human pancreatic cancer cell another 
potential role for miR-34 in cancer initiation and progression linking miR-34a 
to tumor-initiating cells or cancer stem cells (CSC). Another report 
demonstrated that, in CD44 marker-positive versus marker-negative prostate 
cancer cell populations, miR-34a (1p36.22) was prominently under-expressed 
in all populations while the other two miR-34 family members, miR-34b and 
miR-34c (11q23.1), did not show consistent differences between these cells. 
Finally, Guessous has shown that miR-34a reduces glioma stemness and 
induces cell differentiation into astrocytes, neurons and oligodendrocytes. 
Remarkably, in situ hybridization analysis of rat organs showed the highest 
expression of miR-34a within the cerebellum cortex, thus suggesting potential 
biologic roles of the endogenous miRNA in this brain tissues [31]. Emerging 
evidence suggests a role for aberrant miRNA regulation in Neuroblastoma. 
Expression profiling of  miRNAs in Neuroblastoma identified miRNA 
expression signatures that are predictive of clinical outcome. The genes 
encoding miR34-a at 1p36 and miR-125b at 11q24 are frequently deleted and 
have been shown to function as tumor suppressors in Neuroblastoma.  
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1.5 MicroRNAs in the pathogenesis of Neuroblastoma  
With the emergence of an additional complex layer of gene regulation through 
the discovery of microRNAs, there is realistic hope for new insights into the 
complex pathogenesis of Neuroblastoma, which may finally contribute to 
solving open questions and enlightening seemingly paradoxical results. Since 
Neuroblastoma is an embryonal tumor and microRNAs are major regulators of 
differentiation and development, microRNA analysis bears the potential to 
deliver new insights into the pathogenesis of this malignancy . 
MiRNAs regulate gene expression at a post-transcriptional level by inhibiting 
mRNAs from being translated or causing them to be degraded. They play 
major roles in the differentiation of neural cells, and the deregulation of these 
sequences can contribute to tumorigenesis in many forms of cancer. Expression 
profiling of miRNAs in Neuroblastomas has identified a number of miRNAs 
that are differentially expressed in favorable versus unfavorable tumor 
subtypes, particularly with respect to MNA versus non-MNA tumors. 
Functional studies have demonstrated that several miRNAs are able to induce 
apoptosis or differentiation when ectopically over-expressed in Neuroblastoma 
cell lines. Chen and Stallings [32] demonstrated that many miRNA loci are 
differentially expressed in different genomic subtypes of Neuroblastoma and 
that these subtypes can be identified on the basis of miRNA expression 
patterns. It was further noted that a large number of miRNAs appeared to be 
down-regulated in the MNA subtype relative to the 11q- or hyperdiploid 
subtypes, indicating that MYCN might mediate a tumorigenic effect, in part, by 
down-regulating miRNAs that have pro-apoptotic or pro-differentiation effects. 
MiR-184 is an example of a miRNA that is down-regulated in the MNA 
subtype which has pro-apoptotic effects when ectopically up-regulated in 
Neuroblastoma cell lines. Interestingly, a related transcription factor, MYC, 
apparently directly down-regulates a number of miRNA loci in other forms of 
cancer [33]. Fontana et al. demonstrated that the five miRNAs mapping within 
the miR-17-5p-92 polycistronic cluster (miR-17-5p, -18a, -19a, -20a and -92) 
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were expressed at higher levels in Neuroblastoma cell lines exhibiting over-
expression of MYCN relative to cell lines with low levels of this transcription 
factor [34]. In particular, tumors of the MYCN amplified (MNA) subtype 
could be quite accurately classified on the basis of miRNA expression 
profiling, as illustrated in figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Heat map summarizing the patterns of expression for 32 miRNA loci that were 
differentially expressed in  neuroblastoma tumor subtypes (low stage hyperdiploid tumors with 
favorable histopathology, yellow; high stage 11q-tumors with unfavorable histopathology, pink; and 
high stage MYCN amplified tumors with unfavorable histopathology, blue). High expression is 
indicated by red, while low expression is indicated by green. MYCN amplified tumors form a 
distinct cluster characterized by low expression levels of many miRNA loci. The 11q- tumors 
formed two separate clusters, which could not always be perfectly distinguished from the low stage 
hyperdiploid tumors. This figure and its legend was originally published by Chen and Stallings [32]. 
18 
 
In addition to miRNAs behaving in a dominant, oncogenic manner in 
Neuroblastoma, there is also evidence that miRNAs can act in a recessive, 
tumor suppressive fashion. The first miRNA identified in Neuroblastoma with 
tumor suppressor properties was miR-34a. In fact, different studies have 
demonstrated that miR-34a, mapping to a region on chromosome 1p that is 
often deleted in high stage disease, acts as a tumor suppressor in 
Neuroblastoma, as ectopic over-expression of this miRNA decreases cell 
proliferation through the induction of apoptosis. Using array comparative 
genomic hybridization (CGH) data on a published set of tumors, Welch and 
colleagues determined that the region encoding miR-34a is located in the 
minimal region of 1p loss and demonstrated that the expression of miR-34a 
was generally reduced in NB primary tumors as compared to normal adrenal 
gland, and tumors with 1p loss have a 30% reduction in miR-34a expression 
relative to tumors with an intact 1p locus. Similarly, miR-34a expression is 
reduced in the majority of NB cell lines tested. Neuroblastomas only rarely 
harbor p53 mutations, unlike most other tumors. However, attenuation of p53 
function may well still be an important step in Neuroblastomagenesis, and 
achieved via the downregulation of miR-34a through the loss of 1p36. 
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 Aims 
Due to the advances and achievements of genomics, the study of proteins 
encoded by the genome was the next logical step in understanding functional 
aspects of the cell. Powerful nucleic acid approaches are still limited because 
DNA sequences and mRNA levels are not sufficient to predict the amount, and 
activity of the proteins in the cell, moreover the relationships between the 
levels of transcripts and the levels of the proteins encoded by they, does not 
always show direct correlation. Proteome is very dynamic and can change in 
response to cellular or environmental factors. In addition, the proteome is 
orders of magnitude more complex than the genome due to processes such as 
splicing, post-translational events at the protein level, post-translational 
modifications, protein degradation, drug perturbations and disease. 
Furthermore, differences in protein abundance within the cell vary greatly and 
the identification of low abundant proteins remains a challenge. Aim of this 
study is the identification of early direct target of miR-34a in Neuroblastoma, 
observing changes in protein expression induced by miR-34a. Using 
quantitative bottom-up proteomics in two different NBL cell lines, we 
addressed to detected proteins differentially regulated by miR-34a, and among 
these, identify which are the direct targets, that determine the effects on the 
inhibition of the multiple tumor pathways by directly and indirectly regulation 
of numerous critical proteins. Our goal is to determine the complex protein 
network regulated by miR-34a and the effects resulting from this perturbation 
on the cellular system.  
Moreover, another important issue addressed in this thesis is the identification 
of time point of regulation (early or late) in which occurs the greater control on 
protein expression by miR-34a and to demonstrate that miR-34a dinamically 
regulates the expression of proteins involved in several crucial pathways with a 
relative importance in tumor progression.  
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2. Results 
2.1 Conditional miR-34a expression  
One debatable question was related to miR-34a target recognition. At this time 
several miR-34a target genes have been identified, even though a lot remains to 
define. Moreover, in deep knowledge the next step will be the understanding  
how the impairment of miR-34a targets will be exerted on biological pathways, 
defining in this way networks that are directly or indirectly regulated by miR-
34a and this will be of importance for future therapeutic applications.  
To identify miR-34a induced changes in protein expression in Neuroblastoma, 
we generated in two different cell lines, SHEP and SH-SY5Y, several miR-34a 
tetracycline-inducible clones, based on Tet on system (Figure 5).  
 
 
 
 
This system was important to minimize the variability of microRNA 
expression during transient transfection and to minimize, during microRNA 
processing, the side effects on RISC complex obstruction, phenomena that are 
Figure 5. Conditional miR-34a expression. Schematic of the tet-on system in which doxycycline is 
required for activation of miR-34a expression by rtTA.  
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often encountered once a given miRNA is constitutively expressed. Ectopic 
expression of miR-34a in each generated clone was verified by Real Rime PCR 
methodology. We detected a significant fold increase of miR-34a levels in 
tetracycline-treated cells at 6 hours after induction compared to the untreated 
control cells (Figure 6A-B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. mRNA expression levels of miR-34a in inducible stable clones determined by Q-RT-PCR. 
The levels of miR-34a expression in SH-SY5Y (A) and SHEP (B) cells were represented as multiples 
of 2-DCT values compared with non stimulated cells. 
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Among the analyzed clones, we choose in SHEP cell lines the clone ♯D and for 
SH-SY5Y cells the clone ♯4. Both these clones showed low levels of 
endogenous miR-34a and high levels of expression following tetracycline 
stimulation. 
Moreover, to further validate the effect of miR-34a in SH-SY5Y ♯4 cells we 
checked out the expression levels of the previously identified targets, such as 
Survivin and Cyclin D3 [35] [36], observing a decreased protein amount after 
induction of miR-34a expression (see Figure 7). As the ectopic expression of 
miR-34a resulted in the expected effects in SH-SY5Y cells, we employed these 
cells for Shotgun analysis with differential labeling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Western blotting showing the protein expression levels of Survivin and Cyclin D3 in 
SH-SY5Y Tr6 miR-34a compared to empty vector (SH-SY5Y Tr6) at  different time points. Anti 
β-actin was used as the loading control. 
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2.2 Shotgun analysis with differential labeling 
To study the regulatory effects of miR-34a activation, in collaboration with 
Prof. Kris Gevaert (Vlaams Instituut voor Biotechnologie (VIB), Ghent), 
quantitative bottom-up proteomics analysis was applied to measure protein 
response into the previous described cellular models, following induced 
expression of miR-34a by tetracycline. This approach provides the most wide 
and relevant readout being it as direct measurement of the miRNA’s impact on 
entire proteome.  
To achieve this, SHEP-♯D and SH-SY5Y-♯4-TR-miR-34a clones and their 
respective controls (Empty vector- inducible clones) were stimulated with 
tetracycline and cells were harvested at 6, 12 and 24 hours after induction. To 
compare the empty vector-expressing cells with the miR-34a-expressing cells, 
post-metabolic labelling with N-hydroxysuccinimide propionate esters was 
performed:  
•  Empty vector cells = NHS-propionate (12C3)  
•  MiR-34a cells = NHS-propionate (13C3)  
Once the samples were labelled, a short analyses, based on 10 light and heavy 
peptide couples, on the Q-TOF Premier mass spectrometer was performed to 
verify the 1:1 mixing of the labelled samples. Equal amounts of samples were 
mixed together and fractionated by RP-HPLC (Figure 8). This fractionation is 
necessary to avoid a too crowded peptide sample for analysis on the LTQ-
Orbitrap Velos, a hybrid mass spectrometer incorporating the LTQ Velos™ 
dual cell linear trap and the Orbitrap™ analyzer. After this fractionation, 
fractions separated by 20 min were pooled to reduce the number of LC-MS/MS 
runs. For each comparison (empty vector cells versus miR-34a cells), 20 
peptide fractions were analysed on the LTQ-Orbitrap Velos. The results of 
analyses were obtained as the peptide ratio of the light (L) labelled (Empty 
vector - 12C3) versus the heavy (H) labelled sample (miR-34a- 13C3), so:  
L/H Ratio > 1   (down-regulated proteins)  
 L/H Ratio < 1   (up-regulated proteins) 
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 L/H Ratio = 1   (un-regulated proteins). 
          
Prior to calculate ratios, each protein from the acquired data, was identified 
following stringent criteria. Using Mascot database to filter the significant 
identification and quantification,, each protein was defined through the 
identification of at least two unique peptides with confidence settings greater 
than 99%. These points will be detailed in the following paragraphs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.1 Protein identification using Mascot database 
Mascot is a software package from Matrix Science (www.matrixscience.com) 
that interprets mass spectral data into protein identities. Mascot compares the  
experimental spectrum against theoretical spectra determined by the in silico 
Figure 8. Schematic outline of the post-metabolic labelling with NHS-propionylate (C12 and C13) on 
Lysine (K) and Arginine (R) residues coupled with mass spectrometry analysis. Inducible clones of 
mir34a (Tet-on system) in two different neuroblastoma cell lines (SHEP and SH-SY5Y) were 
stimulated with tetracycline to activate miR-34a expression. Once the samples were labelled, samples 
were mixed together in a 1:1 ratio and were fractionated on a RP-HPLC. 
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digestion and fragmentation of known proteins in a sequence database. By 
choosing the best matches between observed and theoretical spectra, Mascot 
infers the amino acid sequences of the peptides in the sample and then attempts 
to group together peptide sequences that could come from the same protein.  
Finally, the protein and peptide identifications are ranked by statistical 
confidence, and reported. Briefly for each match, between an observed 
spectrum and an inferred peptide, is assigned a score based on how well the 
observed spectrum matches the theoretical spectrum for that peptide. This 
number, named Ions Score, is calculated as -10*Log(P), where P is the 
probability that the observed match is a random event (Figure 9).     
 
 
 
 
 
 
 
 
 
 
 
 
Some matches will arise simply by chance and Mascot, to address this, 
calculates a “threshold” score representing a 5% confidence threshold (p 
value), by calculating for each protein reported, an overall Protein Score. The 
Protein Score reflects the combined scores of all observed mass spectra 
assigned to that protein. Protein Scores are non-probabilistic. Further the newer 
Mascot’s release, in its reports include a section called Decoy Search Summary 
(or False Discovery Rate, depending on which report format is used). The 
decoy search estimates the number of false peptide identifications by searching 
Figure 9. Ions score is -10*Log(P) where P is the probability that the observed match is a random 
event. Individuals ions scores > 46 indicate identity or extensive homology (p<0.05). Protein scores are 
derived from ions scores as a non-probabilistic basis for ranking protein hits. 
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the observed data against a ‘decoy’ database – a database that is intended to 
contain only amino acid sequences that are not found in nature. By definition, 
any match between the data and a sequence in the decoy database is a false-
positive. The FDR (false discovery rate) is generally considered a good 
indication of the quality of the experiment. Since most experiments produce a 
large number of peptide identifications, a certain percentage of these 
identifications will, statistically-speaking, be false-positives. For this reason, 
protein identifications based on multiple matching peptides are generally 
considered superior to protein identifications based on a single peptide match. 
The data obtained from the LTQ-Orbitrap Velos were presented to the Swiss-
Prot database, where we searched under the taxonomy “Homo sapiens”. To 
identify the proteins, we linked each sequence to a protein using the Mascot 
database search engine. The identification was carried out with confidence 
settings of 99%. This means that the score always had to be higher than or 
equal to the identity threshold at 99% confidence in order for a peptide 
identification to be noted valid. Quantification was performed by the Mascot 
Distiller algorithm. This algorithm provides “true” and “false” quantifications, 
where the “true” ones are statistically trustworthy, while the “false” ones are 
not. 
 
 2.3 Protein lists and quality control 
Despite the raw data have been cleaned up, the reliability of the identification 
was lifted by adding additional strict filters on the data here analyzed. This 
means that proteins were considered identified when were supported by at least 
two peptides, and one of them must be unique, with a minimum length of eight 
amino acids. By using Knime tool, the data were grouped by sequence and then 
by accession number. Row data were filtered and finally, six peptide lists and 
then six protein lists were created, one for each time point of both cell lines 
(Figure 10). 
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To check the quality of the analysis, a robust statistical analysis was performed. 
Tables 1 and 2 show the median and the standard deviation, based on the “true” 
quantification data in all experiments performed in SHEP and SH-SY5Y cell 
lines respectively: 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Knime workflow showing the path followed to obtain the protein lists 
 
Table 1. Median and standard deviation based on the "true" quantification data of the SHEP empty 
vector versus SHEP miR34a #D at different time points. 
 
  SHEP empty vector vs. 
SHEP miR34a #D at 
time point 6h (log2) 
SHEP empty vector vs. 
SHEP miR34a #D at 
time point 12h (log2) 
SHEP empty vector vs. 
SHEP miR34a #D at 
time point 24h (log2) 
Median 0,105 0,006 -0,315 
Standard 
deviation 
0,462 0,297 0,327 
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The median represents how well the mixing of the light and heavy labelled 
sample was performed, while the standard deviation shows how narrow the 
distribution is. For example, in SHEP #D experiment (time point 12h) we 
obtain a median close to 0 (0.006) and a low standard deviation (0.297), which 
are indications for a good experiment in terms of labelling and mixing. The 
same statistical data are shown in figure 11.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 Data analysis  
 
Table 2. Median and standard deviation based on the "true" quantification data of the SH-SY5Y 
empty vector versus SH-SY5Y miR34a #4 at different time points. 
Figure 11. Normal distribution based on the "true" quantification data of the SHEP empty vector vs. 
SHEP miR-34a #D cells at time point 12h. The black line represents the median and the 2 red lines are 
the outliners calculated on a 99% confidence interval (µ ± (2.58 * SD) =  -0.76 and 0.771). 
 
 
  SH-SY5Y empty vector 
vs. SH-SY5Y miR34a #4 
at time point 6h (log2) 
SH-SY5Y empty vector 
vs. SH-SY5Y miR34a #4 
at time point 12h (log2) 
SH-SY5Y empty vector 
vs. SH-SY5Y miR34a #4 
at time point 24h (log2) 
Median -0,238 -0,08 -0,794 
Standard 
deviation 
0,315 0,285 0,279 
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2.4 Changes in protein expression induced by miR-34a over-expression at 
6 hours  
In order to identify early targets of miR-34a, we firstly focused our attention on 
the differentially expressed proteins at 6 hr after tetracycline induction in both 
NBL cell lines. To achieve this, the protein expression data were filtered based 
on the ratios: proteins with ratios higher than upper limit were considered 
down-regulated, while those with ratios less than the lower limit were 
considered up-regulated. The outlines were calculated on a 99% confidence 
interval. In detail, the area bounded by red lines represents the middle 99% of 
the distribution and stretches from -1.043 to 1.348 in SHEP (Fig. 12A) and 
from -1.05 to 0.575 in SH-SY5Y (Fig. 12B). 
 
 
 
 
 
 
 
 
 
 
 
These limits were computed by adding and subtracting 2.58 standard 
deviations to/from the mean (µ) as follows:   
(µ) - (2.58)(SD) = lower limit 
(µ) + (2.58)(SD) = upper limit 
The value of 2.58 was used according to 99% of confidence. The area of a 
normal distribution is within ± 2.58 standard deviations of the mean; where SD 
is the standard error of the mean.  
 
Figure 12: Normal distribution based on the "true" quantification data of the SHEP empty vector vs. 
SHEP miR34a #D (A) and SH-SY5Y empty vector vs. SH-SY5Y miR34a (B) cells at time point 6h. 
The black line represents the median and the 2 red lines are the outliners calculated on a 99% 
confidence interval (µ ± (2.58 * SD). 
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Applying these computations, we observed in SHEP (log2 ratio < -1.043) and 
in SH-SY5Y (log2 ratio < -1.05) cells lines, respectively 4 and 17 proteins up-
regulated. Analyzing the protein that are negatively regulated, we found 21 
down-regulated proteins in SHEP cells (log2 ratio > 1.348) and 59 in SHSY-
5Y cells (log2 ratio > 0.575) (Figure 13A) . The overlap of proteins down-
regulated in both of these cell lines was 5 proteins (CO1A1, PLEC, PTRF, 
VIME and RRMJ3), as shown in Venn diagram below. A graphical summary 
of protein expression changes resulting by miR-34a expression is presented in 
figure 13B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. A. Down-regulated proteins at 6 hr after 
miR-34a induction  in SHEP and SHSY-5Y cells. The 
table shows the list of the overlapping proteins. B. 
Differentially expressed protein upon miR-34a induction 
in SHEP and SHSY-5Y cells. A median expression 
value equal to 1 was designated black; red, strong 
reduced expression; green, strong increased expression. 
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In order to determine which biological processes (or molecular function) might 
be predominantly affected in the set of proteins that were significantly changed 
by miR-34a overexpression (6 hrs) in each NBL cell line, we performed a Gene 
Ontology analysis. As shown in figure 14, proteins down-regulated by miR-34a 
in SHEP are involved in cytoskeleton organization (18%), apoptosis (8%), 
regulation of transcription (5%), signal transduction (20%), cell motility and 
adhesion (18%), cell division and differentiation (8%).   
 
 
 
 
 
 
 
 
Meanwhile, the functional distribution of down-regulated proteins in SHSY-5Y 
(Figure 15) are: apoptosis (47%), cell division and differentiation (11%),  cell 
motility and adhesion (14%) and mRNA processing (20%). 
 
 
 
 
 
 
 
 
 
 
 Figure 15.  Functional distribution by GO analyses of down-regulated proteins at 6 hr after mir-34a 
induction in SHSY-5Y . 
 
Figure 14.  Functional distribution by GO analyses  of down-regulated proteins at 6 hr after miR-34a 
induction  in SHEP  cell line. 
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Many miRNA targets contain a perfect match to the miRNA seed region in 
their 3’ UTR. We speculated that genes encoded for the 5 overlapping proteins 
have a high probability being direct miR-34a targets. So, to understand if these 
proteins are direct targets of miR-34a, seeing as the “condicio sine qua non” to 
be a target, is the presence of base pairing into the 3’UTR, we searched in these 
transcripts the seed sequences for miR-34a. By using PITA (Probability of 
Interaction by Target Accessibility), a bioinformatics microRNA target 
prediction tool, we found that miR-34a could potentially targets PLEC 
(Plectin), PTRF (Polymerase I and transcript release factor), RRMJ3 (Putative 
rRNA methyltransferase 3) and VIME (Vimentin). For CO1A1 (Collagen 
alpha-1chain) we did not find seed sequence for miR-34a in the 3’UTR, 
probably because it might be directly targetable in the 5’UTR or CDS 
sequences, or most likely because the annotated 3’UTR was incorrect. 
Plectin is a large protein (>500 kDa) of the spectrin superfamily that has long 
been recognized for its ability to bind and link together the three main 
components of the cytoskeleton: actin, microtubules and intermediate filaments 
[37]. Plectin is known to bind integrin α6β4 as the major structural proteins of 
the hemidesmosome, a structure that anchors cells to the extracellular matrix 
[38]. Recently plectin was identified as a putative biomarker in pancreatic 
cancer [39,40]. 
PTRF plays an important role in caveolae formation and organization. Guha 
and colleagues demonstrated that PTRF might be a potentially important 
component of the ERBB signaling network [41].  
Little is known about RRMJ3 (also called FTSJ3). FTSJ3 is a nucleolar protein 
involved in Pre-rRNA processing [42].  
Vimentin, a major constituent of the intermediate filament family of proteins, 
is ubiquitously expressed in normal mesenchymal cells and is known to 
maintain cellular integrity and provide resistance against stress. Vimentin is 
overexpressed in various epithelial cancers, including prostate cancer, 
gastrointestinal tumors, tumors of the central nervous system, breast cancer, 
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malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer 
correlates well with accelerated tumor growth, invasion, and poor prognosis; 
however, the role of vimentin in cancer progression remains obscure. In recent 
years, vimentin has been recognized as a marker for epithelial–mesenchymal 
transition (EMT).  
Taken together, these results show that miR-34a directly targets PLEC, PTRF, 
RRMJ3 and VIME 3’UTR, thus leading to early down-regulation of the 
encoded proteins in both NBL cell lines. Our data also suggest that miR-34a 
inhibits either directly or indirectly signal transduction factor and the 
expression of genes needed for cell proliferation, apoptosis and cell motility.  
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2.4.1 Analysis of proteins down-regulated by miR-34a at 12 hours  
The next step in our investigation was define the effect of miR-34a expression 
on proteome at later time point. For this purpose, we examined the effect of 
miR-34a on proteome 12 hours later the induction. As shown in figure 16, we 
found 26 and 23 significantly down-regulated protein, respectively in SHEP 
and SHSY-5Y. Among these, only one (CO1A1), was already found  down-
regulated at 6 hours, in both cell lines.  
 
 
 
 
 
 
 
 
Considering that the directly regulated genes might vary considerably from cell 
type to cell type or even in the same cell lineage depending on differentiation 
state or environmental conditions, we next combined all the results generated 
by Shotgun analysis at 6 and 12 hours in both cell lines. In this way, we 
obtained a set of 114 proteins regulated by miR-34a: 
 
{Proteins SHEP-6H} U {Proteins SHEP-12H} = { Proteins SHEP-6H/12H} 
{ Proteins
 SHSY5Y-6H} U { Proteins SHSY5Y-12H}= { Proteins SHSY5Y-6H/12H} 
{ Proteins
 SHEP-6H/12H}U { Proteins SHSY5Y-6H/12H}= {114 Proteins} 
 
Then, sorting this protein set for the presence of miR-34a seed-matching 
sequences in the 3’ UTR of their transcripts, we observed that miR-34a could 
regulate the 3’ UTR of 74.9% of this set of proteins. Considering arbitrarily 
significant only prediction sites with ΔΔG values less than -10 (energy-based 
score for microRNA-target interactions equal to the difference between the free 
Figure 16.  Overlap of down-regulated proteins at 12 hr after mir-34a induction  in SHEP and SHSY-5Y 
cells. 
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energy gained by the binding of the microRNA to the target, ΔGduplex, and 
the free energy lost by unpairing the target-site nucleotides, ΔGopen. [43]) , we 
found 33 genes enriched for miR-34a seed sequence (Table 3).  
 
Accession Description 
Median of the 
ratio 
Median of the ratio 
(log2) Sites 
 ΔΔG 
Score 
P19367 HXK1 1,6534475 0,725477238 6 -21,07 
O15231 ZN185 3,045085 1,6064825 5 -16,74 
Q9UG63 ABCF2 1,7913675 0,841061337 7 -15,73 
P15586 GNS 2,66 1,411426246 5 -15,39 
P40261 NNMT 1,9945475 0,996061482 4 -15,31 
Q15746 MYLK 3,28683 1,71669684 10 -15,13 
P07858 CATB 1,64131 0,714847751 9 -14,68 
P30419 NMT1 1,933775 0,951419943 12 -14,57 
P46013 KI67 1,785035 0,835952362 8 -14,46 
P46060 RAGP1 1,527315 0,61099764 2 -13,55 
P13928 ANXA8 2,46724 1,30289806 3 -13,51 
Q9H307 PININ 1,49207 0,577315221 2 -13,51 
Q9NP73 ALG13 2,547845 1,349277513 1 -13,07 
O95340 PAPS2 1,74119 0,80007364 6 -12,85 
Q8WX93 PALLD 1,9598175 0,970719316 9 -12,72 
P06396 GELS 2,549375 1,350143602 3 -12,71 
P13796 PLSL 4,101515 2,036156905 3 -12,71 
Q14651 PLSI 1,49661 0,58169832 4 -12,56 
P21980 TGM2 2,23097 1,157671114 6 -12,43 
Q9Y4K1 AIM1 1,78527 0,836142281 5 -12,31 
Q13510 ASAH1 1,690365 0,757334801 2 -12,1 
Q96MU7 YTDC1 1,8215025 0,865128975 5 -11,97 
P35659 DEK 1,70739 0,771792635 2 -11,95 
Q7Z6K5 CO038 59,93468 5,905319126 6 -11,46 
Q6P1J9 CDC73 181,0392375 7,500158603 3 -11,46 
P07339 CATD 2,08313 1,058752875 3 -11,33 
P09486 SPRC 1,77786 0,830141722 5 -11,3 
Q9NX58 LYAR 2,3192625 1,213666117 1 -10,66 
Q6WKZ4 RFIP1 1,7212 0,783414745 8 -10,39 
Q8WU90 ZC3HF 65,84391 6,040978105 2 -10,28 
Q9Y5L4 TIM13 7,74423 2,953121801 4 -10 
 
  
Table 3.  List of 33 genes enriched for miR-34a seed sequence. 
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Then to improve our target prediction functionality in NBL progression, we 
screen these genes/protein for the correlations of their expression with clinical  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  Expression levels of LYAR, CTCF, TGM2, Ki67, TIMM13, ALG13 and ABCF2 correlation 
to bad clinical outcome in NBL.  
 
38 
 
outcome of NBL patients searching through a public gene expression database 
(http://r2.amc.nl). For this reason further efforts have been addressed to verify 
if any of these genes were correlated to NBL progression and as such would be 
good candidate to further assign a role of miR34a on their regulation.  
Using this flowchart we revealed that, among those analyzed, only n.7 genes 
correlated to worse clinical outcome when overexpressed in NBL (Figure 17). 
These genes are involved in the differentiation (LYAR, CTCF), apoptosis and 
proliferation (TGM2, Ki67), molecular transport (TIMM13 and ABCF2) and 
several metabolic pathway (ALG13). 
To improve the accuracy of target prediction we used other two target 
prediction algorithms: TargetScan and miRanda. We selected as putative 
transcripts regulated by miR-34a, 3’UTR with binding sites for miR-34a 
predicted by at least two of the three bioinformatics algorithms used. 
Interestingly, the seven targets identified that correlated with poor prognosis in 
NBL, were predicted as putative target of miR-34a by at least two of the three 
algorithms used. To test whether the 3’ UTR of each gene could be regulated 
by miR-34a, the 3’ UTR of each gene was cloned downstream a luciferase 
reporter plasmid, and a dual luciferase reporter assay was performed. The data 
obtained confirmed that miR-34a repress the expression of these genes. 
 
LYAR a nucleolar protein, named Ly-1 antibody reactive clone, encodes a 
polypeptide consisting of 388 amino acid residues with a zinc finger motif and 
three copies of nuclear localization signals. The cDNA of LYAR was initially 
isolated from a mouse T-cell leukemia line more than a decade ago. LYAR 
cDNA overexpression in NIH-3T3 fibroblast cells rendered them more 
tumorigenic, indicating that LYAR is a novel nucleolar protein that can be 
involved in cell growth regulation [44]. Recently, microarray data showed that 
LYAR is highly expressed in undifferentiated human ESCs and is significantly 
downregulated upon differentiation [45]. Thus, LYAR appears to be a likely 
candidate for the study of the involvement of nucleolar mechanisms in 
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controlling the selfrenewal of ESCs. Hui Li and colleagues demonstrated that 
Lyar downregulation significantly reduces the rate of ESC growth and 
increases their apoptosis. Moreover, reduced expression of LYAR in ESCs 
impairs their differentiation capacity, failing to rapidly silence pluripotency 
markers and to activate differentiation genes upon differentiation [46]. 
Our data indicated that Lyar was down-regulated in SHSY-5Y cells at 6 hr 
after tetracycline induction of miR-34a and, searching in the 3’ UTR sequences 
of Lyar gene, we found potential binding sites of miR-34a.  
 
CTCF is a highly conserved zinc finger protein implicated in multiple 
regulatory functions, including transcriptional activation/repression, insulation, 
imprinting, and X chromosome inactivation. Various studies reported that 
CTCF is involved in cell cycle arrest, apoptosis, and differentiation processes, 
with the consequence to consider CTCF a potential tumor-suppressor factor. 
But, other studies reported that CTCF protein levels are elevated in both breast 
and lung tumoral cell lines [47,48] and, at least in breast cancer cells, CTCF is 
also associated with apoptosis resistance [47]. These controversial results can 
be elucidated by the role of CTCF as “differentiation-inducing” factor, 
involving disparate pathways depending by cellular context [49-51].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. To determine the expression levels of CTCF in human NBL, we searched through a public 
database (http://r2.amc.nl). This search revealed that is significantly overexpressed in NBL tissues 
compared to normal adrenal gland (p = 2.2 e-6) 
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In fact, it is assumed that each tumoral cell partially possesses the epigenomic 
and proteomic features of its physiological counterpart together with crucial 
alterations that mold its molecular homeostasis and determine CTCF’s 
outcome.  
To determine the expression levels of CTCF in human NBL, we searched 
through a public database of gene expression (http://r2.amc.nl), and we found  
that CTCF is significantly overexpressed in NBL tissues compared to normal 
adrenal gland (p = 2.2 e-6) (Fig.18A).  
 
TGM2 (TG2) Tissue transglutaminase is an important member of the 
transglutaminase family of enzymes that catalyze Ca 2+ -dependent post-
translational modification of proteins. Involvement of TG2 in apoptosis has 
been well established; overexpression of TG2 results in either spontaneous 
apoptosis of cells or rendering cells highly sensitive to apoptosis-inducing 
agents. In contrast with this, recent evidence indicates that increased expression 
of TG2 may prolong cell survival by preventing apoptosis [52].  
TG2 expression is upregulated in drug-resistant and metastatic cancer cells and 
plays a role in the constitutive activation of NF- kB. Increased expression of 
TG2 contributes to increased survival, invasion and motility of breast cancer 
cells [53], cell growth and survival in colorectal cancer [54]. A recent study 
demonstrated that TGF-β-induced TG2 enhances ovarian tumor metastasis by 
inducing EMT and a cancer stem cell phenotype [55]. 
Our data demonstrated that miR-34a leads to a direct down-regulation of 
TGM2 in SHEP cell at 12 hr after induction. Gene expression data revealed 
that TGM2 is overexpressed in advantage stages of NBL (p=2.1e-03), as 
shown in figure 19. 
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ABCF2 The ATP binding cassette (ABC) transporter family acts as an efflux 
pump and its members are related to chemoresistance. ABCF2 is a member, 
which has a chromosome gain at 7q 34-36. Overexpression of ABCF2 was 
found in a chemoresistance clear cell ovarian carcinoma and it was also 
suggested that ABCF2 may contribute to the chemoresistant phenotype  [56]. 
Moreover, ABCF2 protein may be a prognostic marker for ovarian clear cell 
ovarian adenocarcinoma since that higher ABCF2 DNA and mRNA copy 
number and protein levels were found in clear cell cases compared with those 
in serous cases [57]. As shown in figure 20, gene expression data revealed that 
also ABCF2 was found overexpressed in advantage stages of NBL (p=1.9e-
03). 
 
 
 
 
 
 
 
 
 
   Figure 19. Expression levels of TGM2 in different stages of human NBL.  
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KI67 Ki-67 is a protein that in humans is encoded by the MKI67 gene. Antigen 
Ki-67 is a nucleus protein that is strictly associated with and may be necessary 
for cellular proliferation. It was recently reported that Ki67 might be suitable 
for including in the routine clinical practice of breast cancer. For example, 
Ki67 independently improved the prediction of treatment response and 
prognosis in a group of breast cancer patients receiving neoadjuvant treatment. 
A recent study demonstrated that the distribution pattern of Ki67 may be a new 
independent prognostic factor for breast cancer [58].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Expression levels of ABCF2 in different stages of human NBL.  
 
Figure 21. A. Ki67 expression in Neuroblastoma tissues compared to normal adrenal gland (p=9.0 
e-11). B. Ki67 expression in patients with and without 1p36 loss. 
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Ki67 was found overexpressed in Neuroblasoma tissues compared to normal 
adrenal gland (p=9.0 e-11), as shown in figure 21A. Interestingly, in a cohort 
of Neuroblastoma, we observed that patients showing 1p36 loss have high 
expression of Ki67 compared to patients without 1p36 (Fig. 21B)(p=2.4e-03). 
These findings support the notion that Ki67 is regulated by miR-34a. 
 
TIMM13 a member of the “small Tim protein” family, that together with 
Tim8, forms a soluble hexameric 70 kDa complex in the IMS [59]. This 
complex is involved in the import of a number of inner membrane proteins. 
Timm13 is a translocase with similarity to yeast mitochondrial proteins that are 
involved in the import of metabolite transporters from the cytoplasm and into 
the mitochondrial inner membrane.  
 
ALG13 is a subunit of a bipartite UDP-N-acetylglucosamine transferase. It 
heterodimerizes with asparagine-linked glycosylation 14 homolog to form a 
functional UDP-GlcNAc glycosyltransferase that catalyzes the second sugar 
addition of the highly conserved oligosaccharide precursor in endoplasmic 
reticulum N-linked glycosylation. Alg13, as well as Ki67, is highly expressed 
in patients with 1p36 loss (p= 1.1e-03), tumors wherein that there was a loss 
miR-34a genetic locus (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Alg13 expression in patients with and without 1p36 loss. 
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Overall, the importance of the identification of those seven proteins/genes 
found down regulated in NBL upon miR-34a expression is of importance 
because they can be those alternative proteins which may have a role in NBL. 
Further biological functionality mechanistic mode of actions are needed at this 
stage to address those independent protein action within a therapeutic 
intervention of miR34a in the near future. 
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2.4.2 miR-34a regulates a dense network of genes involved in signal 
transduction 
Additionally, biocomputing analyses are then performed to define whether the 
genes regulated by miR-34a together acts in a complex network of molecular 
pathways. To this end, we generated an interactome using the above identified 
proteins. Using MIMI plug-in of Cytoscape program, that retrieves molecular 
interactions [55], we found, as shown in figure 23, that LYAR, TGM2, CTCF, 
TIMM13 and ki67 are strongly linked each other and in turn are linked to the 
components of molecular signaling cascade, already known to be involved in 
Neuroblastoma progression, such as Src-Fyn, Lyn, Myc-p53, Tgf-β, IGF and 
Wnt.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Many of these pathways converge on common downstream effectors that were 
well-established linked to cancer. To verify the effective down-regulation of 
Figure 23. Interactome of LYAR, TGM2, CTCT, TIMM13 and ki67, obtained using MIMI plug-in 
of Cytoscape program. 
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these pathways, we evaluated by Western blotting analysis the WNT pathway 
activation levels in both NBL cells following miR-34a induced expression. For 
this purpose we treated SH-SY5Y and SHEP cells with tetracycline and 
harvested the cells at different time points (6-12-24-48 hrs). We then analyzed 
the expression of activated β-Catenin by using an antibody which is known to 
recognize amino acid residues (aa36-aa44) of human β-Catenin, specific for the 
active form. As shown in Figure 24A, the expression of active β-catenin was 
reduced at 6 hours in SH-SY5Y Tr6 miR-34a#4 compared to SH-SY5Y Tr6 at 
the same time. Similarly, the amount of activated β-Catenin in SHEP Tr6 miR-
34a#D was reduced at 6 and 12 hours and, in the following hours, we did not 
observed substantial variation on activation compared to control cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Total protein extracts prepared from SH-SY5Y Tr6 (A) and SHEP (B) Empty vector (E.V.) 
or -miR-34a overexpressing treated with tetracycline for different time points (6hr, 12hr, 24hr) were 
subject to Western blotting to evaluate Wnt pathway activation. β-Actin (A) and α-Tubulin were used 
as loading controls. 
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Literature data show that GSK-3β plays a major function in WNT signalling 
pathway. The phosphorilation on Ser 9 inhibits the activity of Gsk-3β 
stimulating β-catenin nuclear translocation and enhancing β-catenin/TCF-
mediated transcription. For this reason we then asked whether miR-34a 
overexpression influence the levels of Phospho-Gsk 3β (Ser9). Using Western 
blotting assays, we confirmed that, in SHEP Tr6 miR-34a#D, miR-34a 
overexpression also resulted in the inhibition of Phospho-Gsk 3β (Ser 9) levels. 
Total Gsk 3β was unchanged (Figure 24B). All together, these data indicate 
that the miR-34a led to WNT signaling down-regulation here investigated, thus 
confirming our predicted data. Here we comprehensively demonstrate the 
functional implication of miR-34a capabilities to simultaneously target 
components of several cancer signaling cascade, responsible for tumor 
progression.  
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2.4.3 Identification of late targets of miR-34a 
In order to identify late targets of miR-34a, we analyzed the changes in protein 
expression levels induced by miR-34a 24 hours upon tetracycline stimulation 
and we found n.24 and n.29 proteins down-regulated respectively in SH-SY5Y 
in SHEP. 
Among the 24 down-regulated proteins in SH-SY5Y cells, 9 had already been 
found down-regulated in previously analyzed time points (CATB, ANXA8, 
PLSL, GELS, CATD, SPRC, P4HA1, SODM, FKB10), indicating that still 
remain down-regulated, during miR-34a expression. Western blotting 
presented in figure 25 confirmed that SODM is already down regulated by 
miR-34a at 6 hours after induction and remains so even at 24 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. A. Total proteins prepared from SH-SY5Y Tr6 Empty vector (E.V.) or miR-34a 
overexpression (#4) treated with tetracycline for different time points (6hr, 12hr, 24hr) were subject to 
Western blotting anti-SODM antibody. β-Actin was used as loading control. B. Densiometric  time-
course  analyses  (Active β-Catenin),  as  β-Actin normalized. Data  are  means  ±standard  deviation  
of  3 experiments, each carried out in triplicate 
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Moreover, at this time point in SH-SY5Y has been identified new additional 15 
proteins were found down-regulated. Searching in this protein set, for the 
presence of miR-34a seed-matching sequences in their 3’ UTR transcripts, we 
noticed that miR-34a could potentially regulate the 3’ UTR of 9 of these 
proteins (TBC13, RL1D1, MYO1B, GGA3, STAG2, TXTP, CCD56, DKC1, 
TPM1). While six proteins were annotated as not direct targets of miR-34a 
(SSXT, CC124, ALG5, ALDR, RET1, ULA1). 
Regarding the proteins down-regulated in SHEP, we observed that 12 of 29 
proteins were already found down-regulated at previously analyzed time 
points. Furthermore, 3 proteins (PLSL, CDC73, NOLC1) have been found 
down-regulated only after 24h in SHEP, while in SHSY already at 6 and 12 
hours were inhibited by miR-34a, indicating that the silencing mechanisms, 
that regulate, at post transcriptionally level, the expression of these proteins in 
the two cellular systems are different. Additionally, we found 14 new down-
regulated proteins, 12 of which had miR-34a seed-matching sequences in the 3’ 
UTR of their transcripts (RRP1B, PA1B2, SPSY, FGF2, IMPA3, LRWD1, 
PAPS1, ERAP1, MP3B2, CT043, SRSF1, VP33B). 
Here, we identified additional down-regulated proteins at early time point and 
some of them had putative miR-34a binding sites in their 3’UTR. 
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2.5  The regulation of protein expression by miR-34a is time depending 
In our previous work we demonstrated that miR-34a doesn’t exert its inhibitory 
effect on targets constantly during its expression. For example certain proteins, 
such as DLL1 and Cyclin D1, that were recognized as miR-34a targets, 
analyzed in a time dependent manner, showed fluctuation in their amount of 
protein quota, although the miRNA was continuously expressed [35]. So we 
asked whether there were other proteins in the proteome that do not show a 
constant expression pattern after miR-34a induction. The analyses performed 
above were carried out considering exclusively each time point. In order to 
compare each other the changes in protein expression at different times after 
miR-34a induction, the quantile normalization was applied. The quantile 
normalization generally is used to make two or more distribution identical in 
statistical properties [60,61].  
Applying this technique, we obtained for each experiment (6h, 12 and 24 
hours) a new normalized distributions, as shown by black curves in figure 26A 
and B (upper). Then, to calculate the upper and lower limit to define the 
regulated proteins (as described in the section 3.4), arithmetical mean between 
the new normalized mean (µ) was determined, as shown below: 
1. SH-SY5Y 
• SH-SY5Y 6h (Normalized µ1) 
• SH-SY5Y 12h (Normalized µ2) 
• SH-SY5Y 24h (Normalized µ3) 
Normalized mean (SH-SY5Y 6-12-24h) (µN)= (µ1+ µ2+ µ3)/3= -0.34±0.27 
(Figure XA) 
2. SHEP 
• SHEP 6h (Normalized µ1) 
• SHEP 12h (Normalized µ2) 
• SHEP 24h (Normalized µ3) 
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Normalized mean (SHEP 6-12-24h) (µN)= (µ1+ µ2+ µ3)/3= -0.01±0.32 (Figure 
26B). Figure 26 shows the new normalized values of SHSY-5Y (A) and SHEP 
(B) cell experiments. The new values have the same distribution and can now 
be easily compared each other.  
 
 
 
 
 
 
 
 
 
 
 
 
 
After data normalization, we compared the differentially expressed proteins in 
each experiment and further statistical analyses were performed using Knime 
(Figure 27).  
 
 
 
 
 
 
 
  
 Figure 27 . Knime workflow showing the path followed to obtain the Lorenz curves and Gini                     
coefficient for each protein. 
Figure 26 . To make the three distribution identical in statistical properties a quantile distribution was 
performed. The new normalized distribution of experiments performed in SH-SY5Y cells (A) was µ= 
-0.34±0.27, while in SHEP (B) was µ= -0.01±0.32. 
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To assess trend analysis of the proteins differentially expressed at different 
time points (6h, 12h and 24 hours), Lorenz curve and Gini coefficient were 
evaluated for each protein. The Lorenz curve is a graphical statistic that was 
first introduced in 1905 as a tool for exhibiting the concentration of wealth in a 
population (Lorenz MO, 1905). Originally were used to rank in terms of their 
wealth and the cumulative wealth, the members of the population (on the y-
axis) against the cumulative proportion of the population (on the x-axis). One 
can then select any quantile to characterize concentration using a statistic such 
as ‘Y per cent of the wealth is owned by X per cent of the population’.  
Simply, The Lorenz Curve is a graphical representation of the proportionality 
of a distribution and represents a probability distribution of statistical values. 
Lorenz curve is often associated with income distribution calculations and 
commonly used in the analysis of inequality. Alternatively a summary index of 
concentration, the Gini coefficient (Gini C., 1914), is frequently used. In 
applications, the Gini coefficient frequently accompanies graphical 
presentation of the Lorenz curve. It is often used as a measure of income or 
wealth inequality. In brief, the Gini coefficient is usually 
defined mathematically based on the Lorenz curve, which plots the proportion 
of the total income of the population (y axis) that is cumulatively earned by the 
bottom x% of the population. The line at 45 degrees thus represents perfect 
equality of incomes.  
 
 
 
 
 
 
 
 
 
Figure 28. Graphical 
representation of the Gini 
coefficient. The graph shows 
that the Gini coefficient is equal 
to the area marked A divided by 
the sum of the areas A  and B. 
That is, Gini = A/(A+B). It is 
also equal to 2*A due to fact 
that A+B=0.5 (since the axes 
scale from 0 to 1). 
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The Gini coefficient can then be thought of as the ratio of the area that lies 
between the line of equality and the Lorenz curve (marked A in the diagram) 
over the total area under the line of equality (marked A and B in the diagram); 
i.e.,G = A / (A + B) (Figure 28). A low Gini coefficient indicates a more equal 
distribution, with 0 corresponding to complete equality, while higher Gini 
coefficients indicate more unequal distribution, with 1 corresponding to 
complete inequality. Gini coefficient is a more complex calculation that allows 
us to assess the  whether the  changes, in protein expression level induced by 
miR34a over time, were significant. We evaluated the Lorenz curve for each 
protein of both cell line, as shown in figure 29 and the Gini coefficient, 
applying the formula reported in Materials and Methods section.  
 
 
.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 29.  Lorenz curves of some representative proteins 
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Related to our experiments, a Gini coefficient equal to zero indicates that 
protein shows the same expression pattern at each time point. In this case the 
Lorenz curve overlaps the line of equality. While a Gini coefficient equal to 
one means that protein shows the same expression pattern during the analyzed 
time points; the Lorenz curve is far from the line of equality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.  Expression levels of proteins dynamically regulated by miR-34a over the time in SH-
SY5Y (A) and SHEP (B) cells. The values are expressed as log2 fold change. 
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To select the regulated proteins we used the upper limit of the Gini coefficient 
based on  99% of confidence interval. Our analyses revealed that in SHSY-5Y 
cells, among the 1331 detected proteins, 29 proteins did not show a constant 
expression pattern under time (Figure 30A). While in SHEP cells, 9 of 1067 
detected proteins (Figure 30B) showed an oscillatory expression pattern.  
Another graphical representation of the Gini coefficient is given by the scatter 
plots presented in figure 31. In these graphs were plotted the protein accession 
numbers (x-axis) versus Gini coefficient values (y-axis). The dotted line 
represent the threshold above which the proteins were considered dynamically 
regulated by miR-34a. Our analyses demonstrated that the effect of miR-34a 
down-regulation on this set of proteins, changes during the time.  
This phenomenon may be due to different protein half-life within the cellular 
type, or the presence of other gene/protein factors that could regulate their 
expression as coactivators or repressors or by other mechanisms not yet here 
identified which need a further speculation and supporting data. Thus the finely 
controlled miR-34a machinery here identified regulates several new protein 
function as previously expected. 
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Figure 31. Scatter plots in which were plotted the protein accession numbers (x-axis) and Gini 
coefficient values (y-axis) of SHEP (A) and SY-SY5Y (B) cells. The dotted lines represent the 
threshold to define the proteins that were dynamically regulated.    
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2.5.1 More difference in protein expression at early time point  
Having established that several proteins were regulated in a time-dependent 
manner, we began to investigate when the effects of miR-34a on protein 
expression are more pronounced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Scatter plots comparing protein expression changes between two time points. A.B. Scatter 
plots compare normalized log2 ratio of protein expression at 6 hr (x axis) against 12 hr (y axis) in SH-
SY5Y (A) and SHEP (B) cells. C.D. Scatter plots compare normalized log2 ratio of protein expression 
at 6 hr (x axis) against 24 hr (y axis) in SH-SY5Y (C) and SHEP (D). E.F. Scatter plots compare 
normalized log2 ratio of protein expression at 12 hr (x axis) against 24 hr (y axis) in SH-SY5Y (E) and 
SHEP (F).  
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For this purpose we used the scatter plots graphical representation, to present 
measurements related to two variables. 
Variables used in these graphs represent the fold change of protein expression 
in the same cellular system at two different time of miR-34a induction.  
Scatter plots presented in figure 32, revealed that the magnitude of miR-34a 
effect on protein expression changes occurs at early time (6 hours) when 
compared to the later (12 and 24 hours) proteome output.  
By analyzing normalized log2 ratio at 6h versus normalized log2 ratio at 12h or 
24h the points spread showed higher then when were plotted log2 ratio at 12h 
versus normalized log2 ratio at 24h in both cells lines. All these data suggest 
that the magnitude of miR-34a effects on proteome occurs at early time after 
induction, upsetting all theories hitherto followed, according to which the 
effects on the proteome by a microRNA could be observed only after at least 
24 hours. 
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3. DISCUSSION 
The emergence of shotgun proteomics has facilitated the numerous biological 
discoveries made by proteomic studies. However, comprehensive proteomic 
analysis remains challenging and shotgun proteomics is a continually changing 
field. The proteome is very dynamic and could mutate in response to cellular or 
environmental factors [62]. The identification of miRNA targets, functionally 
important in enhancing tumor capabilities, is crucial for understanding miRNA 
functions. By directly measuring changes in protein production, proteomic data 
are likely to be more relevant than microarray data. Moreover in silencing, 
operated by miRNA, not always were found correspondence between gene 
expression data and protein quota, this due to at least two different post-
transcriptional regulations mechanism [63].  
In this work we analyzed the proteome changes in two different NBL cell lines 
induced by ectopic expression of miR-34a. The analysis presented here 
revealed new direct targets of miR-34a, which presumably represent the 
mediator of its effects. The direct regulation by miR-34a was confirmed by 
reporter gene assays for selected miR-34a target mRNAs, showing that the 
miR-34a-mediated repression of these proteins requires the presence of seed-
matching sequences in the respective 3’-UTRs. 
Among the 2082 detected proteins, 172 were found significantly regulated, 
with 113 proteins being down- and 68 up-regulated. Perhaps surprisingly, the 
repressive effect on individual proteins wasn’t relatively small and often 
exceeded fourfold, although we performed post-metabolic labeling. In effect, 
while in pulsed SILAC (pSILAC) method, only intensity differences between 
newly synthesized proteins (medium-heavy and heavy) are considered, in post-
metabolic labeling there is the problem of persistence of stable proteins, that 
makes difficult to identify the down-regulation. This could also explain the 
reason for which we have not observed the change in protein expression of 
known miR-34a targets. Among the down-regulated proteins, we noted an 
overrepresentation of proteins involved in apoptosis, cell motility, cell division, 
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differentiation and mRNA processing. Even though the down-regulation of 
these proteins, which do not contain predicted miR-34a binding sites in their 
3’-UTRs, presumably might be considered as secondary effect, following the 
direct miR-34a-mediated repression on other proteins that act upstream and 
regulate these functions, it reflects the cell cycle arrest and apoptosis as a major 
consequence of miR-34a activation.  
In our analysis, we identified new targets of miR-34a (Table 3) and among 
these, seven proteins (LYAR, CTCF, TGM2, Ki67, TIMM13, ALG13 and 
ABCF2) have prognostic relevance in NBL. In fact, looking in a public 
database, we observed that all of these seven proteins correlate to bad clinical 
outcome when overexpressed in Neuroblastoma. 
The newly identified miR-34a targets, LYAR, CTCF, TGM2, Ki67 and 
TIMM13 are linked to each other and together converge on important 
pathways involved in tumor progression, such as Wnt, TGF-β, Src/Fyn/Lyn, 
IGF and p53/myc as shown by the network in Figure 23.  
Canonical Wnt signaling controls events ranging from cell fate determination 
and cell cycle regulation to cell motility and metabolism. In addition to the 
importance of the canonical Wnt pathway in normal cell function, pathologic 
increases in Wnt signaling are frequently implicated in neoplastic states. The 
importance of Wnt signaling in human cancer is highlighted by its coordinate 
control of the transcriptional programs underlying EMT, cancer stem cell 
generation and cancer progression. Wnt 1 has been previously been report to be 
a direct target of miR-34a [64] corroborating that miR-34a suppress oncogenic 
Wnt signaling.  
Transforming Growth Factor β (TGF- β) was already found involved in 
signaling controls a diverse set of cellular processes, including cell 
proliferation, recognition, differentiation, apoptosis, and specification of 
developmental fate, during embryogenesis as well as in mature tissues, in 
species ranging from flies and worms to mammals [65-67]. TGF-β suppresses 
early-stage tumor development by virtue of its potent growth inhibitory effect, 
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but becomes a pro-oncogenic factor that stimulates tumor cell growth and 
invasiveness at later stages of tumorigenesis [68,69]. 
Pathological forms of TGFβ signaling promote tumor growth and invasion, 
evasion of immune surveillance, and cancer cell dissemination and metastasis. 
Moreover a recent study demonstrated the capability of miR-34a to target 
genes encoding multiple TGFβ isoforms [70]. The inhibition of these pathways 
by miR-34a was confirmed by literature and data obtained in our laboratory 
[71,72].   
Another important corollary of our analysis here revealed, at the whole-
proteome scale, the demonstration that the miR-34a effects on proteome occurs 
at early time point. In-vitro studies have already shown that miRNAs can 
induce translational inhibition in a very short time frame [73]. Therefore, the 
effects of miR-34a on proteome were investigated in a time-dependent manner, 
following time-courses in NBL cells at 6h, 12h and 24h after miR-34a 
induction. Our results demonstrated that miR-34a expression resulted in a 
regulation of protein expression more evident at 6 hours compared to other 
time points analyzed. At this time point, were found down-regulated 59 
proteins in SH-SY5Y cells and 19 in SHEP. Some of these have seed sites in 
the 3’UTR of their transcripts that can explain the early down-regulation. A 
number of repressed proteins without seeds are nevertheless probably direct 
targets of the miR-34a. However, although some algorithms include searches 
for such sites, it seems that they could not identify these non-canonical sites 
with high success. Another explanation for these repressed proteins without 
seeds could be that are indirectly regulated by miR-34a and that, having a short 
half-life, it is possible to observe the down regulation also in such a short time. 
However we cannot exclude that the target genes that we tested for which we 
did not find miR-34a seed match in the 3’UTR might be direct targets, 
regulated by sequences in the 5’UTR or CDS.  
It is also worth noting that, our data further showed the kinetics of miR-34a 
regulation analyzing here, for the first time the effects of miR-34a on proteome 
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in a time-dependent manner, allowing us to obtain a global picture of miR-34a 
functions. These data provides a clear and effective answer to the long-standing 
question on when miRNA acts on their targets and this is in stark contrast to 
literature data in which miRNA inhibitory effects were evaluated at later time 
point. 
Finally, we observed that the down-regulation of several proteins is maintained 
even in later times, but some proteins were found dynamically regulated over 
time. It is conceivable that such proteins, given the complexity of the system 
here analyzed, belong to key group of proteins, whose expression was finely 
controlled. Thus strengthening our hypothesis that observing the effects of  
micro RNA at a single time point could result in the loss of the identification of 
many target.  
Recently, in vivo studies showed that tumor growth was significantly repressed 
after exogenous miR-34a administration in retroperitoneal Neuroblastoma 
tumors [74]. Identification of miR-34a as is a highly significant finding with 
respect to the development of potential therapeutics for this disease. Current 
therapies for high risk Neuroblastoma include chemo- and radiation-therapy in 
an attempt to hinder tumor relapse. 
Therefore, ectopic miR-34a expression may serve as a tumor therapeutic means 
for human tumors in the future. A comprehensive knowledge of the targets and 
effects of miR-34a is of relevance in order to evaluate the potential side effects 
of such therapies. The study presented here is an important step in the direction 
of obtaining a complete picture of miR-34a targets. In the future, analysis of 
up-regulated proteins may facilitate a more complete coverage of miRNA 
targets. 
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4. Conclusions 
The role of miRNAs in mediating critical cellular processes is an emerging 
field in cancer genetics. Dysregulation, enhanced expression and selective 
inhibition of miRNAs has improved scientific understanding of the functional 
role which these regulatory molecules play in cancer progression and patient 
prognosis. MiR-34a was the first miRNA identified as a putative tumor 
suppressor in Neuroblastoma through its direct targeting of transcription 
factors and other genes essential for cellular proliferation. Here, we identify 
new early targets of miR-34a, adding an important step in understanding the 
mechanisms of action of this microRNA. Although miRNAs are largely known 
to repressively regulate protein expression, it has been reported that some 
miRNAs can also upregulate translation [75]. In this study, we focused on the 
repressive gene regulation of the miRNAs as a result of their binding to the 
3’UTR of target genes, and identified only proteins that were downregulated by 
miR-34a, although many upregulated proteins were also detected by 
quantitative bottom-up proteomics analysis. Further experiments will be 
needed to determine how, mechanistically, miR-34a was able to upregulate 
these proteins. The cell clones here analyzed are now ready for a second level 
of analyses verifying how miR-34a would influence the expression of other 
miRNAs coupled to Long non coding RNAs and how altogether in a 
complexity network of action contribute to NBL progression. These results will 
be issue of future efforts.  
In conclusion, in this work our effort was oriented not only to identify new 
targets of miR-34a in Neuroblastoma, but also to show that the kinetics of 
regulation of  a micro RNA can be very fast and dynamic. 
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Novelties 
 
In this thesis, we identified new targets of miR-34a, some of them with a 
prognostic relevance in NBL. In fact, looking in a public database, we 
observed that these proteins correlate to bad clinical outcome when 
overexpressed in Neuroblastoma. It would be interesting to study the effects of 
such down-regulation given that little is known about the function of these 
proteins in Neuroblastoma,  
Our study also demonstrated that the miR-34a effects on proteome occurs at 
early time point and that the down-regulation of several proteins is maintained 
even in later times. However  some proteins were found dynamically regulated 
by mir-34a over time. These data are important because they open the way to a 
better understanding on the timing and mechanisms of action of a microRNA. 
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5. Materials and Methods 
Cell culture 
The Neuroblastoma cell lines SHEP and SH-SY5Y were kept in RPMI 
medium containing 10% (v/v) fetal calf serum, 2 mM L-glutamine, and 1% 
pen/strep. Cells were transfected with the pcDNA™6/TR plasmid, which 
encodes Tet repressor (TetR) using Lipofectamine2000 (Invitrogen). 
Polyclonal cell pools were generated by selection with blasticidin (5 µg/ml) for 
10 days. Positive clones were transfected with the episomal pT-REx-DEST 
vector encoding miR-34a. Polyclonal cell pools were generated by selection 
with hygromycin (500 µg/ml). The percentage of Tr6/ pT-REx-DEST miR-
34a-positive cells was determined 12 h after addition of tetracycline at a final 
concentration of 2 µg/ml. 
 
RNA extraction and Quantitative Real Time PCR 
Total RNA was extracted from cells using Trizol reagent [Invitrogen] 
according to manufacturer’s recommendations and were treated with RNase 
free DNase [Promega]. Total RNA [1 μg] was reverse transcribed using 
iScriptTM cDNA Syntesis Kit [Biorad]. The RT products [cDNA] were 
amplified by real-time quantitative PCR using 7900 Real-Time PCR System 
[Applied Biosystems, Foster City; CA] with Power SYBR green Master Mix. 
For all SYBR Green PCR, Ct values were normalized to either U6. Relative 
expressions of target genes were determined by the 2–ΔΔCt method. All of the 
data are presented as means ± standard error of two to three replicate 
experiments. 
 
Western blotting  
Cells were washed in cold phosphate-buffered saline and lysed in protein lysis 
buffer (20 mM sodium phosphate, pH 7.4, 150 mM NaCl, 10% glycerol, 1% 
Na-deoxycholate and 1% Triton X-100) supplemented with protease inhibitors 
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(Roche). Cell lysates (50 µg) were electrophoresed on 10% SDS-PAGE gels 
and transferred onto PVDF membranes (Millipore). After 1 hour blocking with 
5% dry milk fat in phosphate-buffered saline containing 0.02% Tween-20, the 
membranes were incubated with the primary antibody overnight at 4 °C, and 
with the secondary antibody for 1 h at room temperature. The bands were 
visualized with a chemiluminescence detection system (Pierce), according to 
the manufacturer instructions.   
 
Shotgun analysis with differential labeling 
To analyze the impact of mir34a activation on protein output we used the post-
metabolic labelling (propionylation) with NHS-propionylate (C12 and C13) on 
Lysine (K) and Arginine (R) residues coupled with mass spectrometry analysis, 
as described above [76]. In breaf, each sample was first desalted by loading 1 
ml of sample on a NAPTM-5 column SephadexTM-G25 DNA Grade [GE 
Healthcare] and then digested by adding trypsin in a trypsin/protein ratio of 
1/50 and incubating overnight at 37 °C. To synthesize isotopically labeled 
reagents NHS-propionate (3 C12) and NHS-propionate (3 C13) was used. Once 
the samples were labelled, a quick analysis, based on 10 light and heavy 
peptide couples, on the Q-tof Premier was performed to determine the 1:1 
mixing of the labelled samples. The samples were mixed together in a 1:1 ratio 
and were fractionated on a RP-HPLC. After the fractionation, fractions with a 
difference of 20 minutes were pooled together to reduce the number of mass 
spectrometry samples. 
 
Knime: The Konstanz Information Miner 
To manipulate the large data set obtain the protein lists, we used Knime. To 
The need for modular data analysis environments has increased dramatically 
over the past years. In order to make use of the vast variety of data analysis 
methods around, it is essential that such an environment is easy and intuitive to 
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use, allows for quick and interactive changes to the analysis and enables the 
user to visually explore the results. 
To meet these challenges a data pipelining environment is an appropriate 
model. It allows the user to visually assemble and adapt the analysis flow from 
standardized building blocks, at the same time oﬀering an intuitive, graphical 
way to document what has been done. Knime, the Konstanz Information Miner 
provides such an environment. 
The Konstanz Information Miner is a modular environment which enables easy 
visual assembly and interactive execution of a data pipeline. It is designed as a 
teaching, research and collaboration platform, which enables easy integration 
of new algorithms, data manipulation or visualization methods as new modules 
or nodes.   
 
MiR 34a target prediction 
MiR-34a targets were selected by examining predicted targets from 
TargetScan, miRanda, and PITA. Each database relies on different algorithms 
of target prediction and uses different read-out scales. Potential gene targets 
were chosen based on the presence in at least two of all of the predicted 
algorithms used in the analyses.  
 
Cloning of 3’ UTRs 
The 3’ UTRs of the indicated target mRNAs containing putative miR-34a 
binding sites were PCR-amplified from human genomic DNA with the Kapa 
HiFi Hot start (Kapa Biosystem). The 3’ UTRs were cloned into pGL3-control-
MCS and verified by sequencing.  
 
Luciferase Assays 
HEK293 cells were seeded in 12-well format and transfected after 48 hours 
with 100 ng of the indicated firefly luciferase reporter plasmid, 20 ng of 
Renilla reporter plasmid as a normalization control, and 25 ng of miR-34a or a 
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negative control oligonucleotide. Luciferase assays were carried out following 
24 hours of transfection using the Dual Luciferase Reporter assay system 
(Promega) according to manufacturer’s instructions. Fluorescence intensities 
were measured with a luminometer (Berthold). 
 
Inequality Measurements 
Fluctuation in protein expression during the time was measured applying the 
Gini’s method, which has been commonly used in the economics and social 
science [18–20]. One of the basic measures of the Gini’s method is the Gini 
coeﬃcient (also known as Gini index), which has been well defined for 
quantifying variable inequalities in a population. For a given variable X, the 
Gini coeﬃcient can be computed with the formula [21] 
G= ( Σ n
 i=1(2i-n-1)X(i)) / (n-1) Σ n i=1 X(i) 
where n (n ≥ 2) is  the number  of considered variable in the population, and X 
(i) is the ith value of considered variable sorted in increasing order, 0  ≤ X (1) ≤ 
X (2) ≤ · · ·  ≤ X (n) .  
The Gini coeﬃcient can be ranged from 0.0 (complete equality) to 1.0 
(complete or absolute inequality). In our experiments a Gini coefficient equal 
to zero indicates that protein shows the same expression pattern at each time 
point, while a Gini coefficient equal to one means that protein shows the same 
expression pattern during the analyzed time points  
 
Statistical Analyses 
All biochemical experiments were done in triplicate unless otherwise stated. 
Two-tailed Student’s t test was used to test significance. Survival curves were 
constructed by the Kaplan and Meier method, with differences between curves 
tested for statistical significance using the log-rank test.  
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